Skip to Content

Tafamidis Dosage

Medically reviewed by Drugs.com. Last updated on Sep 16, 2019.

Applies to the following strengths: meglumine 20 mg; 61 mg

Usual Adult Dose for Amyloidogenic Transthyretin Amyloidosis

Tafamidis meglumine 20 mg: 4 capsules orally once a day (80 mg/day)

Tafamidis 61 mg: 1 capsule orally once a day (61 mg/day)

Comments: Tafamidis and tafamidis meglumine products are not substitutable on a per mg basis.

Use: For the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization.

Renal Dose Adjustments

No adjustment recommended

Liver Dose Adjustments

Mild to moderate liver dysfunction: No adjustment recommended
Severe liver dysfunction: Use with caution

Precautions

CONTRAINDICATIONS: None

Safety and efficacy have not been established in patients younger than 18 years.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Other Comments

Administration advice:
-Tafamidis and tafamidis meglumine are not interchangeable on a per mg basis.
-The capsules may be administered with or without food.
-The capsules should be swallowed whole, not crushed or chewed.

Storage requirements:
-Store at controlled room temperature 20°C to 25°C (68°F to 77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).

General:
-The formulation of these products contains sorbitol, which may affect the bioavailability of other oral medications administered concomitantly.

Patient advice:
-Advise patients to take a missed dose as soon as remembered or to skip the missed dose and take the next dose at the regular time.
-Patients should avoid taking 2 doses at the same time.
-Patients should be advised of the availability of the Transthyretin Amyloidosis Outcome Survey (THAOS) international voluntary registry designed to assess disease progression, genotype/phenotype relationships, and the impact of interventions.
-Advise pregnant women and females of reproductive potential of the potential risk to a fetus and to inform of a known or suspected pregnancy.
-Advise the patient to report pregnancies to the Pfizer reporting line at 1-800-438-1985.
-Advise females not to breastfeed during treatment.
-Patients should be advised to read the FDA-approved patient labeling.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.